Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$160.65 USD
+0.96 (0.60%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $160.64 -0.01 (-0.01%) 7:12 PM ET
4-Sell of 5 4
C Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$160.65 USD
+0.96 (0.60%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $160.64 -0.01 (-0.01%) 7:12 PM ET
4-Sell of 5 4
C Value D Growth F Momentum D VGM
Zacks News
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Should Invesco S&P 500 Low Volatility ETF (SPLV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPLV
3 Dividend Kings Crushing the S&P 500 in 2022
by Derek Lewis
Companies in the Dividend King club carry well-established and successful business operations, clearly displayed by their commendable commitment to shareholders over decades of increased dividend payouts.
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
by Zacks Equity Research
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Should Vanguard High Dividend Yield ETF (VYM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VYM
Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWX
GSK's Q3 Earnings Beat, Ups 2022 Sales Outlook, Stock Up
by Zacks Equity Research
GSK's (GSK) revenues benefit from the strong growth in sales across all segments. The company raises the full-year sales guidance for all its segment
3 Stocks That Popped Yesterday
by Sejuti Banerjea
We're in the middle of earnings season, so it would be natural to assume that earnings reports are the biggest drivers of stocks during the season. But that isn't the case with a bunch that soared yesterday.
Pre-Markets in Green to Start a Fresh Month
by Zacks Equity Research
Pre-Markets in Green to Start a Fresh Month
Pre-Markets Up Ahead of New Fed Hike, Q3 Beats
by Mark Vickery
Big Pharma giants Pfizer (PFE) and Lilly (LLY) posted beats on both top and bottom lines this morning, while J&J (JNJ) is buying Abiomed (ABMD).
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
AbbVie (ABBV) Beats on Q3 Earnings, Lags Sales, Narrows '22 View
by Zacks Equity Research
AbbVie's earnings (ABBV) beat estimates for third-quarter 2022, while sales miss the same. Shares drop in pre-market trading after it narrows down its full-year earnings guidance.
Pharma Stock Roundup: NVS, MRK Report Q3 Earnings JNJ's Tecvayli Gets FDA Nod
by Kinjel Shah
Novartis (NVS) and Merck (MRK) announce Q3 results. FDA approves J&J's (JNJ) multiple myeloma candidate, Tecvayli.
The Zacks Analyst Blog Highlights UnitedHealth Group, Johnson & Johnson, Walmart, The Coca-Cola Company and NVIDIA
by Zacks Equity Research
UnitedHealth Group, Johnson & Johnson, Walmart, The Coca-Cola Company and NVIDIA are part of the Zacks top Analyst Blog.
Pfizer Earnings Preview: Growth & Diversification is Key
by Shaun Pruitt
Pfizer's (PFE) Q3 earnings report on Tuesday, November 1 will give insight into its ability to sustain growth from its Covid-19 vaccines. The company's ability to beat earnings expectations may rely on the growth of other business units during the quarter.
Top Analyst Reports for UnitedHealth, Johnson & Johnson, & Walmart
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Johnson & Johnson (JNJ) and Walmart Inc. (WMT).
Will AbbVie's Immunology Drugs Continue to Drive Q3 Earnings?
by Zacks Equity Research
AbbVie's (ABBV) third-quarter performance is expected to reflect the impact of strong demand for immunology and aesthetics products.
The Zacks Analyst Blog Highlights J&J, Roche, Eli Lilly and AbbVie
by Zacks Equity Research
J&J, Roche, Eli Lilly and AbbVie are part of The Zacks top Analyst Blog.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Should SPDR Portfolio S&P 500 Value ETF (SPYV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPYV
AbbVie (ABBV) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
AbbVie (ABBV) third-quarter performance will likely reflect the impact of strong demand for immunology and aesthetics franchises. Investors will also enquire about ABBV's plans to counter Humira LOE.
Pharma Stock Roundup: JNJ Q3 Earnings Beat, RHHBY Sales Weak, LLY, ABBV Ink M&A Deals
by Kinjel Shah
J&J (JNJ) beats earnings and sales estimates for the third quarter. Eli Lilly (LLY) and AbbVie (ABBV) announce small acquisitions.
Legend's (LEGN) Q3 Carvykti Preliminary Sales Top Expectations
by Zacks Equity Research
Legend Biotech (LEGN) reports $55 million as preliminary sales figures for its multiple myeloma therapy in third-quarter 2022. Shares rise 14.2% post the announcement.
JNJ Beats on Q3 Earnings: ETFs in Focus
by Sweta Killa
Johnson & Johnson (JNJ) continued with its long streak of earnings beat. It outpaced revenue estimates and raised its full-year revenue guidance.
Stock Market News for Oct 19, 2022
by Zacks Equity Research
U.S. stocks ended higher on Tuesday for the second straight day as another batch of solid earnings reports gave investors' confidence a boost.